Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133 cells in triple-negative breast cancer by unknown
Zhang et al. Molecular Cancer 2014, 13:207
http://www.molecular-cancer.com/content/13/1/207RESEARCH Open AccessTwist1 expression induced by sunitinib
accelerates tumor cell vasculogenic mimicry by
increasing the population of CD133+ cells in
triple-negative breast cancer
Danfang Zhang1,2†, Baocun Sun1,2,3,4*†, Xiulan Zhao1,2†, Yuemei Ma1, Ru Ji1, Qiang Gu1,2, Xueyi Dong1, Jing Li1,2,
Fang Liu1, Xiaohua Jia1, Xue Leng1,3, Chong Zhang1, Ran Sun1 and Jiadong Chi1Abstract
Background: Hypoxia induced by antiangiogenic agents is linked to the generation of cancer stem cells (CSCs) and
treatment failure through unknown mechanisms. The generation of endothelial cell-independent microcirculation
in malignant tumors is defined as tumor cell vasculogenic mimicry (VM). In the present study, we analyzed the
effects of an antiangiogenic agent on VM in triple-negative breast cancer (TNBC).
Methods: Microcirculation patterns were detected in patients with TNBC and non-TNBC. Tientsin Albino 2 (TA2)
mice engrafted with mouse TNBC cells and nude mice engrafted with human breast cancer cell lines with TNBC or
non-TNBC phenotypes were administered sunitinib and analyzed to determine tumor progression, survival,
microcirculation, and oxygen concentration. Further, we evaluated the effects of hypoxia induced with CoCl2
and the expression levels of the transcription factor Twist1, in the presence or absence of a Twist siRNA, on
the population of CD133+ cells and VM in TNBC and non-TNBC cells.
Results: VM was detected in 35.8 and 17.8% of patients with TNBC or with non-TNBC, respectively. The growth of
tumors in TNBC and non-TNBC-bearing mice was inhibited by sunitinib. The tumors in TA2 mice engrafted with mouse
TNBCs and in mice engrafted a human TNBC cell line (MDA-MB-231) regrew after terminating sunitinib administration.
However, this effect was not observed in mice engrafted with a non-TNBC tumor cell line. Tumor metastases in
sunitinib-treated TA2 mice was accelerated, and the survival of these mice decreased when sunitinib was withdrawn.
VM was the major component of the microcirculation in sunitinib-treated mice with TNBC tumors, and the population
of CD133+ cells increased in hypoxic areas. Hypoxia also induced MDA-MB-231 cells to express Twist1, and CD133+ cells
present in the MDA-MB-231 cell population induced VM after reoxygenation. Moreover, hypoxia did not induce
MDA-MB-231 cells transfected with an sh-Twist1 siRNA cell to form VM and generate CD133+ cells. Conversely,
hypoxia induced MCF-7 cells transfected with Twist to form VM and generate CD133+ cells.
Conclusions: Sunitinib induced hypoxia in TNBCs, and Twist1 expression induced by hypoxia accelerated VM
by increasing population of CD133+ cells. VM was responsible for the regrowth of TNBCs sunitinib
administration was terminated.
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Breast cancer is the most frequent malignancy among
women worldwide [1]. The status of the expression of
the estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2)
are the most important prognostic markers for invasive
breast cancer [2]. Triple-negative breast cancer (TNBC)
cells do not express ER, PR, or HER2 [3]. TNBC ac-
counts for approximately 15–26% of breast cancer cases
worldwide [4-7]. The survival of patients with TNBC is
shorter compared with that of patients with other breast
cancer subtypes because of the unique genotype and
clinical behavior of TNBC [3]. TNBCs are more likely to
be aggressive and have a higher tendency to metastasize
to visceral organs. Patients with TNBC do not benefit
from endocrine therapy or from anti-HER2 antibody
therapy [8]. Moreover, the chemosensitivity of TNBCs is
limited. Despite clinical trials, an efficacious treatment
for patients with TNBC is not available [9,10].
Antiangiogenic agents such as a anti-vascular endothe-
lial growth factor (VEGF) neutralizing antibody (Avastin,
bevacizumab) and inhibitors of VEGF receptor tyrosine
kinase activity (sorafenib and sunitinib) are key compo-
nents of front-line combination regimens for the treat-
ment of various human cancers [9-11]. These agents are
used to treat non-small cell lung cancer, renal cell can-
cer, and hepatocellular carcinoma [12-14] and were used
to treat metastatic breast cancers in preclinical and clin-
ical studies [15]. However, these and other studies indi-
cate that these therapies may have limited efficacy
[16-18]. Although these agents inhibit the growth of pri-
mary tumors, the responses are usually temporary, and
the overall survival of patients is only modestly increased
[19]. Further, when antiangiogenic agents are adminis-
tered intermittently, for example, sunitinib (4 weeks on
and 2 weeks off ), tumor regrowth is sometimes observed
during drug-free periods or upon termination of treat-
ment [20,21].
Given the limited effect of such treatments, several
clinical trials of sunitinib or bevacizumab to treat breast
cancer were terminated. One study reported increased
tumor invasiveness and metastasis after using VEGF in-
hibitors or inactivating VEGF gene expression in mouse
models of cancer [22]. These reports suggest that the
rationale and prospects of antiangiogenic therapies for
breast cancer treatment must be re-evaluated. Because
of this, we asked two questions as follows: 1. What is
the mechanism of antiangiogenic treatment failure? 2. Is
there any difference in the responses to anti-VEGF agents
of patients with TNBC or non-TNBC?
In 1999, Maniotis et al. reported the discovery of vas-
culogenic mimicry (VM), a vascularization of malignant
tumors [23]. VM channels are formed by tumor cells but
not by endothelial cells. VM occurs in many aggressivetumors such as melanoma, inflammatory breast carcin-
oma, prostate carcinoma, ovarian carcinoma, hepatocellu-
lar carcinoma, and gastrointestinal stromal tumors [24-28].
Tumors with VM are more aggressive, and patients have a
poorer prognosis than those without VM.
We proved that hypoxia induces VM, and uncovered
evidence that cancer stem cells (CSCs) may play an im-
portant role in VM [29,30]. Moreover, administration of
antiangiogenic agents induces intratumoral hypoxia, and
hypoxia increases the number of CSCs in cell lines de-
rived from glioblastomas and breast cancers [31]. Based
on these results, we hypothesized that intratumoral hyp-
oxia induced by antiangiogenic agents accelerates VM
channel formation in TNBC by increasing the popula-
tion of CSCs, which in turn, causes tumor regrowth, me-
tastases, and treatment failure using antiangiogenic
agents. This hypothesis is supported by the results of the
present study that includes an analysis of human pa-
tients with TNBC and non-TNBC as well as studies con-
ducted in vivo and in vitro using mice that develop
spontaneous TNBC and nude mice engrafted with hu-
man breast cancer cell lines with TNBC and non-TNBC
phenotypes.
Results
Pathological and clinical features of TNBC
The expression of ER, PR, and HER2 was determined
using immunohistochemistry (IHC), and positive samples
were assigned a staining index value >1 (see Methods).
Among the 174 patients with breast cancer selected for
this study, 67 were diagnosed with TNBC (TNBC group)
according to lack of detection of ER, PR, and HER2
(Figure 1A). The remaining 107 patients were designated
the non-TNBC group. The TNBC group had small, poorly
differentiated and highly mitotic tumor cells, and necrosis
was present in the center of the tumor nests. Table 1 sum-
marizes the pathological and clinical features of the pa-
tients in each group. The median ages at diagnosis of
patients in the TNBC and non-TNBC groups were 47 and
51 years, respectively. Approximately 11.9 and 4.7% of
these respective patients were <40 years of age (χ2 = 3.148,
P = 0.076). Grade III disease was diagnosed in 28.4 and
20.0% of the TNBC and non-TNBC groups, respectively
(χ2 = 5.746, P = 0.039). At diagnosis, 62.6 and 32.7% of the
TNBC and non-TNBC groups presented with axillary
node metastasis (χ2 = 4.078, P = 0.048), respectively, and
17.9% of the TNBC group was diagnosed with clinical
stages TNM II or III (χ2 = 6.347, P = 0.050). Distant me-
tastases were present in approximately 14 and 3.8% of
the TNBC and non-TNBC groups, respectively (χ2 = 6.077,
P = 0.024).
One hundred eighteen patients were alive at the end
of the follow-up period, December 2008. The mean sur-
vival of all patients was 120.7 ± 3.9 months. The survival
Figure 1 Characterization of the TNBC and non-TNBC groups. Patients were diagnosed with TNBC or non-TNBC using immunohistochemical
criteria and group accordingly (see Methods section). A) H&E staining and IHC analysis of ER, PR, and HER2 expression in tumor sections. Tumor
nests comprised poorly differentiated highly mitotic small tumor cells in patients with TNBC, and necrosis was present in the center of the tumor
nests (indicated by the black arrow). B) IHC analysis of CD31 expression indicates endothelium-dependent vessels (EDV) in sections from patients
with TNBC and non-TNBC. CD31/PAS double-staining shows more VM channels in TNBC sections. The arrow indicates a VM channel formed by
PAS-positive matrix and tumor cells in a TNBC section. C) Comparison of the density of EDVs between groups. D) Overall survival of patients with
TNBC and non-TNBC. Kaplan–Meier analysis indicates that the prognosis of the TNBC group was poorer (χ2 = 7.587, P = 0.006). Scale bar = 100 μm.
The error bar indicates the standard deviation (SD).
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of the TNBC group was 67.1%. The mean survival
times of the non-TNBC and TNBC groups were
128.7 ± 4.15 months and 106.1 ± 7.01 months, respect-
ively (Figure 1D, χ2 = 7.587, P = 0.006).
Comparison of microcirculation patterns of the TNBC and
non-TNBC groups
Using IHC, we analyzed tissues for the expression of
CD31 and together with PAS staining was performed to
investigate microcirculation patterns. Detection of CD31
expression shows that the number of endothelial vessels
in the TNBC group was higher compared with that of the
non-TNBC group (Figure 1B and 1C, respectively; t =
2.033, P = 0.044). VM channels that did not express CD31
but stained with PAS (Figure 1B) were identified in
approximately 35.8% of the TNBC group and in 17.8%of the non-TNBC group (Figure 1B, Table 1, χ2 = 5.327,
P = 0.002).
Effects of sunitinib on TA2 mice engrafted with mouse
TNBC cells and nude mice engrafted with human cell
lines with non-TNBC and TNBC phenotypes
To study the effect of anti-angiogenesis agents on TNBC,
TNBC-bearing TA2 mice were treated orally with suniti-
nib using a clinically relevant schedule. TA2 breast can-
cers comprise mainly small round cells with a small
cytoplasm. These cancers readily metastasize to the lungs,
liver, and spleen (Additional file 1: Figure S1A-S1D). Be-
cause immunohistochemical analysis of tumors did not
detect the expression in tumors of ER-α, PR, or HER-2
(Additional file 1: Figure S1E-S1G), we defined the spon-
taneous breast cancers of TA2 mice as TNBC. Conversely,
the expression p53, PCNA, cyclin D1, and cytokeratin 5/8
Table 1 Comparison of pathological and clinical features








<40 8 (11.9) 5 (4.7) 3.148 0.076
≥40 59 (88.1) 102 (95.3)
Primary tumor
size (diameter)
d<2 cm 17 (25.4) 14 (13.1) 4.659 0.097
2≤ d<5 cm 43 (64.2) 76 (71.0)
d ≥5 7 (10.4) 17 (15.9)
Grade
I and II 48 (71.6) 73 (80.0) 5.764 0.039
III 19 (28.4) 34 (20.0)
Axillary node status
Negative 25 (37.4) 72 (67.3) 4.078 0.048
Positive 42 (62.6) 35 (32.7)
TNM stage
I 13 (19.4) 16 (15.0) 6.374 0.050
II 42 (62.7) 84 (76.6)
III 12 (17.9) 9 (8.4)
VM
No 43 (64.2) 88 (82.2) 5.237 0.002
Yes 24 (35.8) 19 (17.8)
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S1H-S1K). Therefore, we used these mice as a model for
assessing the effects of sunitinib on TNBC.
The mice were treated with sunitinib or placebo for
8 days. The tumors grew at a significantly slower rate in
the sunitinib-treated mice compared with those adminis-
tered placebo (Figure 2A). All TA2 mice in the treat-
ment group were alive on day 17, in contrast to <40% of
controls (Figure 2B). The sizes of the tumors in mice
treated with sunitinib increased after treatment was ter-
minated. Moreover, the survival rate of the treatment
group decreased similarly to that of the placebo group
after treatment was withdrawn. Moreover, after sunitinib
treatment was terminated, the spleens of the placebo-
treated and sunitinib-treated mice were significantly
enlarged compared with those during treatment with su-
nitinib (Figures 1A and 2B). Additional metastatic sites
were identified in the lung, liver, spleen, kidney, and
peritoneal cavity of the control group (Figure 2D). How-
ever, bone metastasis was not detected in the animals of
all groups (Figure 2D). The organ structures that were
disrupted by the metastatic breast cancer cells are shown
in Figure 2E.We next tested the effects of sunitinib on mice engrafted
with either TNBC MDA-MB-231 cells (with the TNBC
phenotype) or with MCF-7 cells (with the non-TNBC
phenotype). Sunitinib inhibited the growth of tumors in-
duced by MDA-MB-231 or MCF-7 cells (Figure 3A). The
tumors formed by MDA-MB-231 cells, but not by MCF-7
cells, regrew when treatment was terminated (Figure 3A).
None of the mice in either group died.
Hypoxia induced by sunitinib accelerates the generation
of CSCs and VM in TNBC
To determine the mechanism of the regrowth and me-
tastasis of TNBCs after terminating sunitinib treatment,
we performed endomucin/PAS double-staining, immuno-
fluorescence analysis of endomucin and CD133 expres-
sion, and Hydroxyprobe analysis of oxygen concentration
to determine the microcirculation patterns, the presence
of CSC populations in the different treatment groups, and
the number of hypoxic cells.
Endothelial vessels and VM were observed in TA2 tu-
mors and those formed by MDA-MB-231 cells, and VM
channels were detected not in tumors formed by MCF-7
cells (Figures 3B and 4A). The number of VM channels in
TA2 and MDA-MB-231 tumors increased significantly
after sunitinib treatment, and the number of endothelium-
dependent vessels decreased (Figures 3B-3E and 4A-4D).
Endothelial vessels reappeared in TA2 and MDA-MB-231
tumors after treatment was terminated; however, no sig-
nificant difference was observed in the epithelial vessels
after terminating sunitinib treatment of MCF-7 tumors
(Figures 3B-3E and 4A-4D).
Hypoxyprobe analysis confirmed that increased numbers
of hypoxic tumor cells were present in TA2 and MDA-
MB-231 tumors compared with those of the other groups
(Figures 3C and 4C). More CD133+ cells were detected
in TA2 and MDA-MB-231 tumors compared with the
controls and after treatment was terminated. CD133+
MDA-MB-231 tumor cells were observed in the center
and at the periphery of the hypoxic areas, and the numbers
of CD133+ MCF-7 tumor cells were similar in all groups
(Figures 3C, 3F and 4C, 4E).
Hypoxia induces the formation of VM-like channels
and the generation of MDA-MB-231-CSCs by
up-regulating the expression of proteins associated
with VM
To investigate the relationship between hypoxia gener-
ated by inhibitors of VEGF signaling and VM of human
TNBCs, we induced hypoxic conditions in vitro using
CoCl2. Normoxic MDA-MB-231 cells formed VM-like
channels, and the number of these channels increased
after CoCl2 treatment and reoxygenation (Figure 5A). This
result was accompanied by a dynamic change in the ex-
pression of HIF-1α expression and an increased Twist1
Figure 2 Effect of sunitinib on the survival, growth, and metastasis of TA2 mice with TNBC. A) Tumor growth curve of sunitinib- and
placebo-treated groups (N = 20 per group). B) Survival of groups treated with sunitinib or placebo. C) Analysis of the weights of lungs, liver,
spleen, and kidneys. D) Percentage of mice with metastases in different organs. More metastatic sites were identified in the lungs, liver, spleen,
kidneys, and peritoneal cavity of the mice in the control group, and the number of metastases increased when treatment was terminated.
E) Morphology of metastatic sites in treated and control groups (H&E staining). The scale bar = 100 μm, and the error bar indicates the
SD. TB: terminal bronchiole; G: glomerulus; PA: portal area; WB: white pulp; RB: red pulp.
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TNBC cells, hypoxia introduced Twist1-independent VE-
cadherin up-regulation; however, the VM-like channel for-
mation by MCF-7 cells was not affected by reoxygenation
(Figure 5A and 5B).We next determined the effects of hypoxia on the gen-
eration of human breast cancer CSCs and the relationship
between hypoxia and VM. FACS analysis indicated
that the CD133+ population of MDA-MB-231 cells in-
creased significantly after CoCl2 treatment, whereas that
Figure 3 Effect of sunitinib on nude mice engrafted with MDA-MB-231 and MCF-7 cells. A) Tumor growth curves of (N = 20 per group).
B) Microcirculation patterns. The number of EDVs decreased in sunitinib-treated mice with MDA-MB-231 tumors, and more VM channels
were observed during and after these mice were treated with sunitinib compared with mice bearing MDA-MB-231-induced tumors that
received placebo. The EDVs rebounded after the treatment of mice with MDA-MB-231 tumors. VM channels did not form in mice with
MCF-7 tumors. The arrows indicate the VM channels formed by PAS-positive matrix and tumor cells. C) Immunofluorescence analysis of
endomucin and CD133 expression and Hydroxyprobe analysis of oxygen levels. More Hypoxyprobe-positive cells were observed in the
mice with tumors formed by MDA-MB-231 and MCF-7 tumors treated with sunitinib compared with those in the control group. The
hypoxic area in tumors formed by MDA-MB-231 cells disappeared when treatment was terminated, and EDVs rebounded upon treatment.
Conversely, there was no significant difference between mice with tumors formed by MCF-7 cells during or after treatment with sunitinib.
CD133+ cells were present in MDA-MB-231 tumors in the center and periphery of the hypoxic area. The number of CD133+ cells in
MCF-7 tumors did not differ among groups. D) Quantification of VM. VM channels were not observed in MCF-7 tumors. E) Quantification
of EDVs. F) Quantification of CD133+ cells. More CD133+ cells were present in the MDA-MB-231 tumors in mice treated with sunitinib
compared with those in other tumors. Scale bar = 100 μm, and the error bar indicates the SD.
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munofluorescence analysis of CD133 expression by cells
cultured in Matrigel shows that CD133+ MDA-MB-231
cells survived hypoxia and formed a stem-cell sphere.
Moreover, we detected CD133 in the tumor cells lining the
VM channels but not in distantly located cells (Figure 5E).Effects of twist1 on CD133 expression and VM-like channel
formation by breast cancer cells
We used siRNA techniques to investigate the role of
Twist1 in vasculogenic mimicry induced by TNBCs and
the generation of CD133+ cells under hypoxia. Twist1
expression was inhibited or increased in MDA-MB-231
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fected with Twist1. Transfected MDA-MB-231 cells did
not form VM-like channels under normoxia, hypoxia, or
reoxygenation, and CD133 expression was inhibited as
well (Figure 6). MCF-7 cells that expressed higher levels of
Twist1 formed VM channels under conditions of nor-
moxia and reoxygenation. Moreover, the tumor cells lining
the VM channels expressed CD133 (Figure 6).
Discussion
Vasculogenic mimicry occurs in over 10 tumor types
[23,32] that are characterized as highly aggressive, poorly
differentiated, and highly metastatic [32,33]. Therefore,
patients with tumors characterized by vasculogenic mim-
icry have poor outcomes compared with those without
VM [24]. Compared with other tumors, TNBCs are larger,
higher grade, more aggressive, and they present with
lymph node involvement [4,7,34]. We found that VM oc-
curs more frequently in patients with TNBC compared
with those with non-TNBC, which strongly supports the
conclusion that VM indicates poor prognosis.
Hendrix et al. proposed that tumor cells with embryonic
phenotypes are highly plastic and form VM channels [33].Figure 4 Sunitinib-induced hypoxia accelerates the generation of CSC
patterns of tumors in mice treated with sunitinib. The number of EDVs dec
treatment compared with the animals administered placebo. Numerous ED
indicate the VM channels formed by PAS-positive matrix and tumor ce
channels increased during and after sunitinib treatment. C) Immunofluoresce
analysis of oxygen levels. More tumor cells were detected using the Hypoxyp
D) Quantification of EDVs. E) Quantification of CD133+ cells in tumors. M
Scale bar = 100 μm, and the error bar indicates the SD.The genes that express proteins that contribute to the
formation of VM channels are specifically expressed
by endothelial and hematopoietic stem cells [35,36].
Recent reports indicate that CSCs may be involved in
VM in glioblastomas, breast cancers, and hepatocellu-
lar carcinomas [30,37]. Hepatocellular carcinoma cells
that form VM channels express CSC markers such as
SOX2 and OCT4 (Sun BC et al. unpublished observa-
tions). Glioma cancer stem cells enriched in the human
glioblastoma cell line U87 form VM channels in xenograft
transplantation [37].
Analysis of the gene expression profiles of 587 patients
with TNBC shows enrichment of markers specific for
stem cells or mesenchymal stem cells [38]. The epithelial-
to-mesenchymal transition (EMT) is important in VM.
Moreover, genes encoding proteins associated with the
EMT are expressed at high levels in this population of pa-
tients [39]. Moreover, these results suggest that the gene
expression fingerprint of TNBC determines the ability of
TNBCs to form VM more efficiently compared with non-
TNBCs.
Bevacizumab and sunitinib in combination with cyto-
toxic drugs were administered in phase III trials of patientss and VM in breast tumors of TA2 mice. A) Microcirculation
reased and more VM channels were present in mice during and after
Vs rebounded when treatment was discontinued. The arrows
lls. B) Quantification of VM channels in the treatment groups. VM
nce analysis of endomucin and CD133 expression and Hydroxyprobe
obe in the tumors of mice treated with sunitinib, and most were CD133+.
ore CD133+ cells were present in the sunitinib-treated tumors.
Figure 5 (See legend on next page.)
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Figure 5 Hypoxia induces VM-like channel formation by up-regulating the expression of proteins associated with VM and by generating
MDA-MB-231 CSCs. A) Matrigel cell culture under a CoCl2-induced hypoxia. MDA-MB-231 cells formed VM-like channels (arrow) on Matrigel
under normoxia, and more VM-like channels (arrows) were formed after reoxygenation. In contrast, hypoxia and reoxygenation did not affect
VM-like channel formation by MCF-7 cells. B)Western blot analysis shows that hypoxia and reoxygenation induced and inhibited HIF-1α expression,
respectively, in MDA-MB-231 and MCF-7 cells. However, reoxygenation induced the expression of Twist1 and VE-cadherin only in MDA-MB-231
cells. C) Representative FACS analyses of the CD133+ populations of MDA-MB-231 and MCF-7 cells in normoxia and hypoxia. The arrow shows
the increase in the CD133+ population under hypoxia. D) Quantification of the CD133+ population under normoxia and hypoxia. E) MDA-MB-231
cells formed a VM-like channel on Matrigel in normoxia and were CD133−. The MDA-MB-231 cells that survived hypoxia were spherical, similar to
stem cells and expressed CD133 (arrowheads). The tumor cells that line the VM channels were CD133+ (arrows), whereas the cells far from VM were
CD133−. The scale bar = 100 μm, and the error bar indicates the SD.
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ated for treating patients with early-stage breast cancer as
a neoadjuvant [40]. The failures of these trials recently pro-
voked several debates regarding the future applications of
anti-VEGF agents in breast cancer [20,41]. Aside from the
failure of anti-VEGF agents to treat breast cancer, the re-
sults of clinical and preclinical research show that they
have limited efficacy for treating hepatocellular carcinoma,
rectal cancer, and glioblastoma [14]. These treatment fail-
ures may be explained as follows [16,19]: (i) some breast
cancers are highly angiogenic and express low levels of
VEGF; (ii) numerous proangiogenic growth factors such as
PLGF, PDGFBB, and bFGF are present and can be up-
regulated to drive angiogenesis when the VEGF pathway is
inhibited [10]; and (iii) antiangiogenic therapy can increase
tumor hypoxia, which induces an increase in HIF-1α ex-
pression to levels sufficient to activate genes that encode
proteins required for the growth, invasion, and metastasis.
In the present study, sunitinib was administered to TA2
mice engrafted with tumors of the TN phenotype thatFigure 6 Effects of Twist1 levels on CD133 expression and VM-like ch
form VM-like channels when Twist1 expression was inhibited under con
expression was inhibited as well. When Twist1 expression was up-regulated, M
reoxygenation. Moreover, the tumor cells that lined the VM channels were CDwere derived from TA2 spontaneous breast cancers [42].
The growth of primary tumors and metastases were typic-
ally inhibited by sunitinib treatment, and the survival of
the treated mice increased from 40 to 100%. However, the
mice suffered from tumor regrowth and metastases when
treatment was suspended, which decreased to those of the
control group.
Our previous study reveals “three stages of tumor
microcirculation” in melanomas [32]. VM channels, mo-
saic blood vessels, and endothelial vessels coexist in a
malignant tumor and can transform into each other by
changes in the tumor microenvironment [29,43]. Because
VM occurs in TNBC, we investigated the microcirculation
patterns of the sunitinib-treated tumors and observed
numerous VM channels when endothelial vessels were
inhibited by sunitinib. After discontinuing treatment, the
number of endothelial vessels increased and were linked
to the VM channels.
The VEGF signaling pathway is essential in endothelial
cell-dependent angiogenesis. However, VM is independentannel formation by breast cancer cells. MDA-MB-231 cells did not
ditions of normoxia, hypoxia, and reoxygenation, and CD133
CF-7 cells formed VM channels under conditions of normoxia and
133+. The error bar = 100 μm, and the error bar indicates the SD.
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are blocked by anti-VEGF agents, VM can be triggered to
provide blood to promote tumor growth and metastasis.
Moreover, VM is responsible for regenerating the endo-
thelial vessels when treatment is discontinued in this
study. These results implicate VM in the failure of
standard antiangiogenic therapy to kill aggressive tu-
mors. Therefore, devising strategies that combine standard
VEGF-targeted therapies or an endothelium-dependent
drug with VM-targeted therapies is attracting considerable
interest [44].
A hypoxic tumor microenvironment is the most im-
portant inducer of VM [28,29,39]. Consistent with these
findings, we show here that sunitinib inhibited endothe-
lial vessels, produced additional hypoxic areas in TNBC-
bearing TA2 mice, and increased the number of VM
channels. These results are consistent with our previous
finding that hypoxia of the ischemic back limb promotes
VM in the B16 melanoma mouse model. We also found
that CoCl2-induced hypoxia increased the number of VM-
like channels of MDA-MB-231 cells cultured in Matrigel
in the present study.
The mechanism responsible for the effects of hypoxia
on VM is unknown. The downstream effectors of HIF-
1α are associated with angiogenesis, cell proliferation,
cell survival, and glucose/iron metabolism. Hypoxia is
linked to increased numbers of CSCs in glioblastoma and
breast cancer, and CSCs are involved in tumor angiogen-
esis and VM [31,45,46]. The breast cancer cells of TA2
mice expressed increased levels of CD133 under hypoxia
after sunitinib treatment. Further, hypoxia induced an in-
crease in the population of CD133+ MDA-MB-231 cells in
vivo. Moreover, stem cells that formed spheres survived
and expressed CD133 under hypoxia. Only the CD133+
cells formed VM channels in Matrigel after reoxygenation,
suggesting that hypoxia accelerates VM by stimulating the
CSC population.
We found that the EMT factor Twist1 induced the ex-
pression of VE-cadherin to promote VM in hepatocellular
carcinoma [28]. Hypoxia induces an EMT-like phenotype
in cancer cells [47], and HIF-1α regulates the expression
of Twist1 by binding directly to the hypoxia-response
element (HRE) in the proximal promoter of Twist1. EMT
can induce stem-cell generation by normal and tumor
cells [48,49]. We show here that MDA-MB-231 cells with
up-regulated Twist1 expression increased the CSC popu-
lation after reoxygenation. Therefore, more VM channels
were generated by cells cultured in Matrigel.
Hypoxia did not significantly affect the CSC population
in cultures of MCF-7 cells, and Twist1 expression was
down-regulated after reoxygenation. Inhibiting Twist1 ex-
pression by MDA-MB-231 cells caused the loss of VM
channels in Matrigel and decreased the number of CD133+
cells in hypoxic cultures. MCF-7 cells that expressed Twist1gained the ability to form VM channels and generate
CD133+ cells. These results highlight the complexity of
the mechanism that regulates the EMT and the biology of
CSCs. Human mammary epithelial cells are transformed
by Twist1 and snail, and they exhibit the characteristics of
CSCs, including the formation of mammospheres, col-
onies in soft agar, and tumors in vivo [49]. For example,
Borgna et al. found that MCF-7 cells gain mesenchymal
features by enriching for CSCs in short-term mammo-
sphere culture [50]. Whether the EMT regulates CSCs or
CSCs regulate the EMT is unknown.
Therefore, hypoxia induced by sunitinib accelerates
VM by increasing Twsit1 expression and the population
of CSCs in TNBC. This finding may explain the ineffi-
cacy of antiangiogenic agents in certain breast cancers.
Most important, Twist1 and related signal transduction
pathways may serve as targets for treating TNBC.
Conclusions
Sunitinib induced hypoxia in TNBCs, and Twist1 ex-
pression induced by hypoxia accelerated VM by increas-
ing the size of the population of CD133+ cells. VM was
responsible for the regrowth of TNBCs sunitinib admin-
istration was terminated.
Methods
Reagents and cell culture
The primary antibodies used in this study are listed in
Additional file 2: Table S1. All secondary antibodies were
purchased from Zhongshan Golden Bridge Biotechnology
Co., Ltd. (Beijing, China). Sunitinib malate (S-8803)
was purchased from LC Laboratories (MA, USA). The
Hypoxyprobe-1 Kit (HP1-1000Kit) was purchased from
Hypoxyprobe, Inc. (MA, USA). The human breast cancer
cell lines MCF-7 and MDA-MB-231 and breast cancer
cells of TA2 mice were cultured in RPMI-1640 medium
with 10% FBS, 4 mM L-glutamine, and 1% penicillin-
streptomycin. Matrigel (BD Bioscience, NY, USA) was
diluted with RPMI-1640 medium.
Patient samples
The Tianjin General Hospital Ethics Committee approved
the studies of humans. The patients were informed of the
aims, methods, and other details of the present study. All
clinical investigations were conducted according to the
principles stated in the Declaration of Helsinki. We col-
lected samples from 174 patients with breast cancer with
detailed pathological and clinical information. All patients
underwent surgery and chemotherapy in Tianjin General
Hospital from 1997 to 2004. The median age of the pa-
tients was 51.0 years (range, 31–74 years). All patients had
invasive breast cancer, and axillary node metastases were
present in 76. The diameter of the primary tumor in 31
patients was <2 cm and >5 cm in 24 patients. The follow-
Zhang et al. Molecular Cancer 2014, 13:207 Page 11 of 14
http://www.molecular-cancer.com/content/13/1/207up period started at the time of the surgery and ended in
December 2008.
Tissue microarrays and scoring methods
Formalin-fixed, paraffin-embedded tissues from the pa-
tients were analyzed after H&E staining. Specific tissue
samples were chosen to create tissue microarrays with
1-mm cores (1.5-mm between cores). Tissue microarrays
were analyzed using IHC according to a standard proto-
col [43]. Protein expression levels were quantified ac-
cording to the method of Sun et al. [43]. Staining was
scored as follows; 0 = undetectable, 1 = weak, 2 =moder-
ate, and 3 = strong. The number of positive cells out of
100 tumor cells per field was visually evaluated and
scored as follows: 0 < 10% positive, 1 < 25%, 2 < 50%, and
3 > 50%. The staining index or the sum of the staining
intensity and the positive-cell score were used to deter-
mine the result for each sample. A sample was defined
as positive when the staining index was >1. VM and
endothelial vessels were counted at 400× magnification,
and the score for each sample was defined as the average
of 10 fields-of-view.
TA2 and nude mouse models of TNBC
Tianjin Medical University Ethics Committee approved
the protocols for using animals. All steps were carefully
administered to protect the welfare of the animals and
prevent their suffering. The Tientsin Albino 2 (TA2)
mice were provided by the Animal Center of Tianjin
Medical University. TA2 mice develop spontaneous
breast cancer with the TN phenotype at high incidence
(showed in Additional file 3), and we used these tumors
to induce tumors in TA2 mice [42]. Nude mice were
purchased from Beijing HFK Bioscience Company. Ap-
proximately 1 × 106 TA2 breast cancer, MDA-MB-231,
and MCF-7 cells were injected subcutaneously into the
backs of 6-week-old female nude mice (N = 20 per
group, respectively). Tumors were measured every
2 days, and tumor size was calculated using a standard
formula (length × width2 × 0.52). The TA2 mice with
breast cancer were administered sunitinib daily when
the tumor reached 0.2 cm3. Sunitinib was administered
to nude mice when the size of tumors induced by
engrafted MDA-MB-231 and MCF-7 cells was approxi-
mately 0.05 cm3. Sunitinib (60 mg/kg) was administered
orally for 8 days, and distilled water was used as the pla-
cebo. Survival was closely monitored daily at least three
times. All surviving mice were sacrificed 1 week after
treatment was terminated. Pimonidazole-HCl was injected
intraperitoneally (60 mg/kg) 60 min before the mice were
sacrificed. The primary tumors and metastatic sites in
the peritoneal cavity, lungs, liver, spleen, kidneys, and
femurs were collected, weighed, and fixed with 4%
paraformaldehyde (PFA). All organs and tumors wereembedded in paraffin, and 5-μm-thick sections were
prepared.
Hypoxic cell culture in vivo
MDA-MB-231 and MCF-7 cells were seeded into 96-well
plates or on Matrigel-coated slides. Cells were treated with
40 μg/ml CoCl2 in cell culture medium for 30 h, and then
the hypoxic medium was removed and replaced with nor-
mal medium. After 40 h, the cells or slides were harvested,
and images were acquired using an inverted microscope
(ECLIPSE TS100, Nikon).
Western blotting
HIF-1α, Twist 1, and VE-cadherin expression was ana-
lyzed using western blotting. Lysates were prepared
using a buffer containing 1% SDS, 10 Mm Tris–HCl,
pH 7.6, 20-μg/ml aprotinin, 20-μg/ml leupeptin, and 1-
mM AEBSF. The protein concentration of lysates was
measured using the Bradford method. Approximately
20 μg of protein was separated on an 8% SDS-PAGE gel
and electroblotted onto a PVDF membrane. After blocking
with 5% fat-free milk in TBS-Tween overnight, the mem-
brane was incubated with primary antibodies overnight at
4°C. After washing with TBS-Tween three times, the mem-
brane was labeled with horseradish peroxidase-conjugated
anti-goat IgG (1:1,000) for 1 h at room temperature (RT).
Blots were developed using a DAB kit, GAPHD was used
as an internal control, and the bands were analyzed using a
gel imaging system (Kodak).
Fluorescence-activated cell sorting (FACS) analysis
Suspensions of MDA-MB-231 and MCF-7 cells were
fixed in 75% cold ethanol, and 106 cells were incubated
with anti-CD133-PE antibody solution or isotype control
on ice for 15 min before they were washed, resuspended
in staining buffer (2% fetal calf serum in PBS), and ana-
lyzed using a FACS Accuri C6 (BD Biosciences). Gates
were set with isotype controls for each cell so that <1%
of the cell population was false-positive. The labeled
cells were then analyzed (10,000 events).
Immunohistochemical and immunofluorescence assays of
formalin-fixed, paraffin-embedded tissues
Formalin-fixed, paraffin-embedded tissues were sectioned,
dewaxed, and rehydrated using graded concentrations of
alcohol. Endogenous peroxidase was blocked using 5%
goat serum at RT for 10 min. The sections were heated in
a microwave oven in citrate buffer for 20 min. The slides
were incubated with primary antibodies overnight at 4°C,
washed with PBS, and individually incubated with biotin-
labeled or FITC-labeled secondary antibodies. The color
was developed using DAB. The sections were counter-
stained with hematoxylin or DAPI and observed using a
microscope (80i, Nikon).
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acid Schiff (PAS) double-staining
After immunohistochemical analysis of sections for
CD31 expression, the sections were exposed to 1% so-
dium periodate for 10 min, washed for 5 min in distilled
water, and then incubated for 15 min with PAS at 37°C.
The sections were counterstained with hematoxylin and
observed using a microscope (80i, Nikon).
Immunofluorescence analysis of cells cultured on Matrigel
MDA-MB-231 and MCF-7 cells cultured on Matrigel-
coated slides were washed with PBS twice, permeabilized,
and fixed in 2% PFA and 0.1% Triton X100 in PBS buffer
at 4°C for 30 min. The slides were then washed three
times with PBS and incubated with 10% goat serum in
PBS. The cells were then incubated with the primary anti-
bodies at 4°C overnight, washed three times with PBS con-
taining 0.1% Tween-20 for 15 min, and incubated with the
secondary antibodies for 2 h at RT. The slides were
washed with PBS and mounted using a slow-fade Light
Anti-fade Kit (Zhongshan Golden Bridge). All matched
samples were photographed using a confocal laser scan-
ning microscope (A1, Nikon).
Expression plasmids and twist1 gene silencing
A full-length Twist1 complementary cDNA was ampli-
fied using PCR from a library of normal human embryo
cDNA digested with XhoI/EcoRI and subcloned into
pcDNA3.1 vectors [28]. The constructs were confirmed
by DNA sequencing. A small interfering RNA (siRNA) kit
(pGP-Twist1-shRNA) was purchased from GenePharm
(Shanghai, China). The target sequence (5′-AAGCTGAG
CAAGATTCAGACC-3′ [siTwist1 nucleotides 505–525])
was used to inhibit Twist1 expression in vitro [28]. A non-
silencing siRNA sequence (target sequence 5′-AATTCT
CCGAACGTGTCACGT-3′) was used as a negative control.
Statistical analysis
SPSS version 11.0 (Chicago, IL, USA) was used to evaluate
the data. The χ2 test was performed to assess the patho-
logical and clinical characteristics of the TNBC and
non-TNBC groups. The survival of these two groups was
evaluated using Kaplan–Meier analysis. The two-tailed Stu-
dent t test was performed to compare the endothelial ves-
sels of the human breast cancers, tumor growth, metastasis,
and CD133+ cells between groups. The survival rate of the
tumor-bearing mice was evaluated using Kaplan–Meier
analysis. Statistical significance was defined as P < 0.05.
Additional files
Additional file 1: Figure S1. Morphologic characteristics and
phenotype of TA2 breast cancer. (A) Spontaneous breast cancers in TA2
mice are mostly composed of poorly differentiated cells and form varioustumor nests separated by well-developed stroma. Necrosis (arrow) is
frequently found in the center of the tumor. (B) Metastatic tumor nodule
in the lung. (C) Metastatic sites in the liver. (D) Metastatic sites in the
spleen. (E), (F), and (G) show that TA2 breast cancer cells are negative for
ER α, PR, and HER-2. (H) Moderate expression of p53 is identified in
tumor cells. (I) Expression of cyclin D1 is detected in TA2 breast cancer.
(J) PCNA expressed in TA2 breast cancer. (K) Expression of Cytokeratin
5/8, a myoepithelium marker, is found in tumor cells. Ruler is 100 μm.
Additional file 2: Table S1. Primary antibodies used in this study.
Additional file 3: Supplementary data.
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